Emory University scientists collaborated with scientists from the Walter Reed Army Institute of Research (WRAIR) to measure the plasmablast response induced in human subjects following administration of two candidate dengue vaccines. Researchers first vaccinated with a live-attenuated dengue vaccine and then "boosted" with a purified inactivated dengue vaccine. WRAIR and GlaxoSmithKline (GSK) co-developed both of these candidate vaccines.
An Emory University researcher provided Kineta with in vivo data. The Emory University researcher licensed a virus strain and provided its animal model set up guidance.
MSD provided an Emory University researcher studying tuberculosis with membrane-bound protein purification expertise.
University of Mauritius, Northeastern University, and Emory University researchers collaborated to assess the efficacy of tuberculosis drugs using different delivery strategies.
Dr. Liotta had developed nucleoside analogs for a variety of viral diseases and was interested in assessing their promise as new therapies against several DNA and RNA viral pathogens, including dengue, Rift Valley fever, Ebola, influenza, adenovirus, and human herpesviruses. However, he did not have the capacity in his laboratory to do multiple viral family screenings. BVGH connected Dr. Liotta and colleagues with Drs. Cassetti and Tseng, who arranged for NIH-funded contractors to test the compounds in vitro for efficacy against many DNA and RNA viral families. These projects have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, under contract numbers: HHSN272201100008I, HHSN272201100013I, HHSN272201100016I, and HHSN272201100019I.